99 results about "Feeder Cell" patented technology

The present invention discloses a method for improving growth and survival of single human embryonic stem cells. The method includes the step of obtaining a single undifferentiated HES cell; mixing the single undifferentiated cell with an extracellular matrix (ECM) to encompass the cell; and inoculating the mixture onto feeder cells with a nutrient medium in a growth environment. Therefore the single cells can survive, proliferate and grow in vitro.

The present invention relates to a pharmaceutical composition comprising of preparations of human embryonic stem (hES) cells and their derivatives and methods for their transplantation into the human body, wherein transplantation results in the clinical reversal of symptoms, cure, stabilization or arrest of degeneration of a wide variety of presently incurable and terminal medical conditions, diseases and disorders. The invention further relates to novel processes of preparing novel stem cell lines which are free of animal products, feeder cells, growth factors, leukaemia inhibitory factor, supplementary mineral combinations, amino acid supplements, vitamin supplements, fibroblast growth factor, membrane associated steel factor, soluble steel factor and conditioned media. This invention further relates to the isolation, culture, maintenance, expansion, differentiation, storage, and preservation of such stem cells.

Human non-embryonic adult totipotent and pluripotent stem cells are isolated in a simplified serum-free and feeder cell-free process. Most remarkably, certain stem cells, and especially BLSCs, are extremely small, fail to exclude trypan blue, but are nevertheless able to proliferate from even high dilutions. Therefore, so obtained stem cells can be used to prepare true monoclonal stem cell populations, which are useful in numerous uses, including therapeutic, prophylactic, diagnostic, and research uses.

The invention relates to a method of realizing the screening and the monoclone preparation of hybridoma cell in one step. The method comprises that the semisolid medium of the monoclone of hybridoma cell is firstly prepared, the basic fibroblast growth factor of human is added into the fusion cell, then hydridoma fusion factor and clone factor are added and well-mixed, then the mixed material and the semisolid medium are gently well-mixed and packaged into plates and cultivated in the condition of 35 DEG C and CO2 with concentration of 5 percent; when visible clone colony grows in the plates, the clone is aspirated from the culture medium by a micropipettor and moved onto a cell culture plate for liquid scale-up culture, and one clone is moved in one hole; till the cell grows to half to two-third of the hole bottom, the culture supernatant is aspirated to do positive detection, and the positive hole is chosen to directly scale-up frozen and stored for further carrying out the characteristic identification of antibody or ascites production. The method of realizing the screening and the monoclone preparation of hybridoma cell in one step has the advantages of the simple operation, the short culture period, not requiring feeder cells and easily achieving the screening and the monoclone preparation of hybridoma cell after cell fusion in one step.

The invention relates to a serum-free medium of embryonic stem cells, and its application. The medium comprises a micro-molecular inhibitor CHIR99021, a micro-molecular inhibitor XAV939, an additive B27/N2 and a basic medium DMEM/F12. The serum-free medium of embryonic stem cells, which contains no animal source substances and has a determined composition, is obtained by using the micro-molecular inhibitor CHIR99021, the micro-molecular inhibitor XAV939 and the B27/N2 additive having a clear composition to substitute serum and feeder cells in a traditional embryo hepatocyte medium. Experiments prove that the medium can maintain the self updating of human embryonic stem cells, and maintains the undifferentiated state and totipotency of the embryonic stem cells; and the medium has a clear composition, and proteins and other components contained in the medium are from human recombinant proteins or are obtained through chemical synthesis, so there is no embryonic stem cell pollution, thereby no corresponding immune response is excited, and no immune immunological rejection is initiated.

The present invention relates to a culture system for and a method for propagation of human blastocyst-derived stem cells (hBS cells) upon enzymatic dissociation into a single cell suspension. The culture system for propagation of human blastocyst-derived stem (hBS) cells comprises i) human feeder cells at a density of at least 50,000 cells/cm<2>, ii) one or more dissociation agents for dissociation of hBS cell colonies into a single cell suspension, and iii) a supportive culture medium, which culture system makes it possible to propagate hBS cells by dissociation of hBS cell colonies into a single cell suspension at each consecutive passage for an extended time period, while maintaining the significant characteristics of hBS cells.

It has been found that when pluripotent stem cells are cultured in the presence of hepatocyte differentiating agents, a population of cells is derived that has a remarkably high proportion of cells with a stem cell phenotype. In one example, human embryonic stem cells are allowed to form embryoid bodies and then mixed with the differentiation agent n-butyrate, optionally supplemented with maturation factors. In another example, n-butyrate is added to human embryonic stem cells in feeder-free culture. A remarkably homogeneous population of cells was obtained in both methods, consisting primarily of cells with morphological characteristics of hepatocytes, expressing characteristic surface markers of hepatocytes, and also possessing enzymatic and biosynthetic roles important for liver function. Since hepatocytes readily proliferate in culture, this system provides a rich source of hepatocyte lineage cells for various uses, such as drug screening and supplementation of liver function in clinical therapy.

Provided is a method of preparing induced pluripotent stem cells using a synthetic peptide, and more particularly, to a method of preparing induced pluripotent stem cells using a peptide capable of inhibiting the activity of NF-κB and promoting mesenchymal-epithelial transition (MET). Since undifferentiated multipotent stem cells may be efficiently prepared under xenopathogen-free or feeder cell-free conditions without requiring co-culture with animal serum or xenogeneic cells, the method for preparing the induced pluripotent stem cells using the synthetic peptide according to the present disclosure is very useful for developing stem cell therapeutic agents that are clinically applicable.

Various embodiments of the present invention include compositions, materials and methods for maintaining and propagating mammalian mesenchymal stem cells in an undifferentiated state in the absence of feeder cells and applications of the same.

The present invention addresses the problem of providing a method for differentiating primordial germ cells into functionally mature GV stage oocytes by in vitro culture. The present invention pertains to a method for differentiating primordial germ cells into functional GV stage oocytes in vitro including (a) a step for forming secondary follicles by culturing primordial germ cells and feeder cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or factors having a similar function to estrogen, (b) a step for partially cleaving the bonds between the granulosa cell layer and the thecal cell layer among the oocyte, granulosa cell layer, and thecal cell layer that constitute the formed secondary follicles, and (c) a step for differentiating the oocytes into functional GV stage oocytes by culturing the oocytes and granulosa cell layer that constitute the secondary follicles and the thecal cell layer in medium including a polymer compound.

The present invention relates to improved continuous (immortalized) cell lines, in particular keratinocytes and melanocytes derived from normal human skin tissue. The present invention also relates to novel serum-free media for isolating, producing and maintaining said improved continuous keratinocyte and melanocyte cell lines. The present invention also relates to methods for producing primary melanocytes and keratinocytes under serum-free conditions without any feeder cells.

The invention discloses a preparation method of feeder cells for rapid culture of tumor infiltrating lymphocytes. The preparation method comprises the steps that peripheral blood lymphocytes are treated by using mitomycin C to obtain the feeder cells, and then the feeder cells and pre-cultured tumor infiltrating lymphocytes are co-cultured. The efficiency of expanding the tumor infiltrating lymphocytes of the feeder cells produced by the preparation method is better than that of the feeder cells produced by gamma-ray irradiation, and meanwhile the cost of using the preparation method is significantly lowered. The preparation method is simple and easy to operate, and can be widely applied and promoted.